Results 121 to 130 of about 1,314 (191)

Efficacy and safety of fluocinolone acetonide intravitreal implant (0.2 µg/day) in patients with post-surgical inflammation associated with macular edema: a case series study

Journal of Ophthalmic Inflammation and Infection
Background Postoperative cystoid macular edema (PCME) is a primary cause of reduced vision following both cataract and/or vitreoretinal surgery, which may spontaneously resolve.
Maria Madeira, Ana Cabugueira, Helena Urbano, Miguel Cordeiro, Marta Guedes   +4 more
doaj   +1 more source

Clinical efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: five-year real-world results. [PDF]

Eye (Lond), 2023
Dobler E, Mohammed BR, Chavan R, Lip PL, Mitra A, Mushtaq B.   +5 more
europepmc   +1 more source

Challenging Clinical Cases – A Walk Through Supplemental Therapy with Intravitreal Ranibizumab Therapy Following Treatment of Diabetic Macular Edema with the 0.19 mg Fluocinolone Acetonide Implant (ILUVIEN®)

International Medical Case Reports Journal, 2020
Bernardete Pessoa,1,2 João Melo-Beirão,1,2 Angelina Meireles,1,2 Pedro Menéres1,2 1Ophtalmology Department, Centro Hospitalar e Universitário do Porto, Porto, Portugal; 2Unit for Multidisciplinary Research in Biomedicine ...
Pessoa B, Melo-Beirão J, Meireles A, Menéres P   +3 more
doaj  

Real-world safety and efficacy of 0.19 mg fluocinolone acetonide intravitreal implant in the management of recurrent non-infectious uveitis [PDF]

, 2022
Christensen, Louise Fischer, Vorum, Henrik   +1 more
core   +3 more sources

Early adoption of the fluocinolone acetonide (FAc) intravitreal implant in patients with persistent or recurrent diabetic macular edema (DME)

International Medical Case Reports Journal, 2019
Jessica D McCluskey, Paul L Kaufman, Kathy Wynne, Gregory LewisDepartment of Ophthalmology, Thomas Eye Group, Atlanta, GA, USAObjective: To assess long-term outcomes for effectiveness, safety, and treatment burden after injection of 0.2 μg/day ...
McCluskey JD, Kaufman PL, Wynne K, Lewis G   +3 more
doaj  

The efficacy and safety outcomes of the 0.19 mg fluocinolone acetonide implant after prior treatment with the 0.7 mg dexamethasone implant in patients with diabetic macular edema

International Medical Case Reports Journal, 2018
P Singh,1 A Chedid,1 SK Deuchler,1 T Kohnen,2 M Müller,2 FH Koch1 1Retina and Vitreous Unit, University Eye Clinic, Frankfurt am Main, Germany; 2Ophthalmology University Eye Hospital, Frankfurt am Main, Germany Purpose: There are little or no ...
Singh P, Chedid A, Deuchler SK, Kohnen T, Müller M, Koch FH   +5 more
doaj  

Management of Steroid Induced Glaucoma following the Iluvien (Fluocinolone) Implant: A UK Survey [PDF]

Journal of Ophthalmic Research and Ocular Care, 2020
Vithlani Sejal, Zambarakji Hadi
openaire   +1 more source

A novel intravitreal fluocinolone acetonide implant (Iluvien®) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series

Clinical Ophthalmology, 2015
Vera K Schmit-Eilenberger Augenklinik Städtisches Klinikum, Karlsruhe, Baden-Württemberg, Germany Background: Iluvien® is a novel, nonbiodegradable, sustained-release drug delivery system (0.2 µg/d fluocinolone acetonide [FAc ...
Schmit-Eilenberger VK
doaj  

The Use of Sustained Release Intravitreal Steroid Implants in Non-Infectious Uveitis Affecting the Posterior Segment of the Eye. [PDF]

Ophthalmol Ther, 2022
Abdulla D, Ali Y, Menezo V, Taylor SRJ.
europepmc   +1 more source

Recurrence rates in ocular non-infectious uveitis according to US FDA criteria or Rest of World criteria. [PDF]

J Ophthalmic Inflamm Infect, 2022
Jaffe GJ, Pavesio CE.
europepmc   +1 more source